Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents

Caroline Diorio, Laura Hernandez-Miyares, Diego A. Espinoza, Brenda L. Banwell, Amit Bar-Or, Amanda M. DiNofia, Allison Barz Leahy, Zachary Martinez, Regina M. Myers, Sarah E. Hopkins, Susan R. Rheingold, David T. Teachey, Angela N. Viaene, Lisa M. Wray, Shannon L. Maude, Stephan A. Grupp, Jennifer L. McGuire

Blood (2024) 144 (13): 1387–1398.

https://doi.org/10.1182/blood.2024023933

Published: 2024

Includes: Supplemental data

Journal Articles

IL-10 Levels Differentially Regulate IFNg Signaling of CART19 and CART22

Caroline Diorio, Regina M. Myers, Anastasia Frank-Kamenetski, Rawan Shraim, Amanda M. Dinofia, Zachary Martinez, Ohaila Mustafa, Joseph A Fraietta, Vanessa Gonzalez, Vivian Yi, Lahari Uppuluri, Haley Newman, Edward Behrens, Carl June, Scott Canna, Stephan Grupp, David T. Teachey

Blood (2023) 142 (Supplement 1): 3431.

https://doi.org/10.1182/blood-2023-182377

Published: 2023

Journal Articles

Outcomes and Toxicities after Allogeneic Hematopoietic Cell Transplant for Remission Consolidation or Relapse Therapy after CD19 Chimeric Antigen Receptor T Cell Therapy in Children and Young Adults with Acute Lymphoblastic Leukemia

Regina M. Myers, Sarah Mumanachit, Shannon L. Maude, Amanda M. Dinofia, Jason L. Freedman, Nancy Bunin, Lisa Wray, Allison Barz Leahy, Timothy S Olson, Stephan Grupp, Alix E. Seif, Caitlin W. Elgarten

Blood (2023) 142 (Supplement 1): 3767.

https://doi.org/10.1182/blood-2023-188047

Published: 2023

Journal Articles

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Blood (2022) 140 (Supplement 1): 2376–2377.

https://doi.org/10.1182/blood-2022-168139

Published: 2022

Journal Articles

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 256.

https://doi.org/10.1182/blood-2021-153336

Published: 2021

Journal Articles

Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Regina M. Myers, Kaitlin Devine, Yimei Li, Sophie Lawrence, Allison Barz Leahy, Hongyan Liu, Lauren Vernau, Colleen Callahan, Diane Baniewicz, Stephan Kadauke, Regina McGuire, Margaret A Cameron, Amanda M. DiNofia, Susan R. Rheingold, Richard Aplenc, Carl H June, Stephan A. Grupp, Lisa Wray, Shannon L. Maude

Blood (2021) 138 (Supplement 1): 474.

https://doi.org/10.1182/blood-2021-147299

Published: 2021

Journal Articles

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Blood (2021) 138 (Supplement 1): 167.

https://doi.org/10.1182/blood-2021-149477

Published: 2021

Journal Articles

Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL

Benjamin J Lerman, Yimei Li, Hongyan Liu, Regina M. Myers, Kaitlin Devine, Colleen Callahan, Diane Baniewicz, Stephan Kadauke, Amanda M. DiNofia, Susan R. Rheingold, Lisa Wray, Richard Aplenc, Stephan A. Grupp, Shannon L. Maude, Allison Barz Leahy

Blood (2021) 138 (Supplement 1): 1747.

https://doi.org/10.1182/blood-2021-151114

Published: 2021

Journal Articles

Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019

Regina M. Myers, MD, Julie C Fitzgerald, MD, Amanda M. DiNofia, MD, Lisa Wray, MD, Allison Barz Leahy, MD, Yimei Li, PhD, Laura Smith, RN, MSN, CRNP, Evanette Burrows, MPH, Mark Ramos, BS, Laura S Motley, BSc, BSN, RN, Raabia N Khan, MPH, Kelly D Getz, Richard Aplenc, MD PhD, Stephan Grupp, MD PhD, Shannon L. Maude, MD PhD

Blood (2019) 134 (Supplement_1): 61.

https://doi.org/10.1182/blood-2019-126724

Published: 2019

Journal Articles

Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy

Allison Barz Leahy, MD, Kaitlin J. Stanley, MD, Regina M. Myers, MD, Amanda M. DiNofia, MD, Lisa Wray, MD, Susan R. Rheingold, MD, Colleen Callahan, CRNP, Diane Baniewicz, CRNP, Amy E. Barry, PPCNP-BC, Maria M. Patino, BS, Stephen P. Hunger, MD, Stephan Grupp, MD PhD, David M. Barrett, Shannon L. Maude, MD PhD

Blood (2019) 134 (Supplement_1): 1464.

https://doi.org/10.1182/blood-2019-130060

Published: 2019

Journal Articles

Using Administrative Data to Identify Relapse and Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Lymphoblastic Leukemia (ALL): Validation at Two Centers and Incidence Estimation in a National Cohort

Viviane C. Cahen, Yimei Li, PhD, Caitlin W Elgarten, MD, Amanda M. DiNofia, MD, Jennifer J. Wilkes, MD, Lena E. Winestone, MD, Yuan-Shung V. Huang, MS, M. Monica Gramatges, MD PhD, Karen R. Rabin, MD PhD, Brian T. Fisher, DO, Kelly D Getz, PhD, Richard Aplenc, MD PhD, Alix E. Seif, MD

Blood (2018) 132 (Supplement 1): 624.

https://doi.org/10.1182/blood-2018-99-114228

Published: 2018

Journal Articles

A Novel Approach to Identifying Septic Shock (SS) in Children with Acute Lymphoblastic Leukemia (ALL) Using Pediatric Health Information System (PHIS) Data: Methods Validation and Incidence Estimation in a National Cohort

Viviane C. Cahen, Yimei Li, PhD, Evanette Burrows, MPH, Caitlin W Elgarten, MD, Amanda M. DiNofia, MD, Jennifer J. Wilkes, MD, Lena E. Winestone, MD, Yuan-Shung V. Huang, MS, Julie C Fitzgerald, MD, M. Monica Gramatges, MD PhD, Karen R. Rabin, MD PhD, Brian T. Fisher, DO, Kelly D Getz, PhD, Richard Aplenc, MD PhD, Alix E. Seif, MD

Blood (2018) 132 (Supplement 1): 3597.

https://doi.org/10.1182/blood-2018-99-114235

Published: 2018

Journal Articles

Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

Amanda M. Li, MD, George E Hucks, Amanda M. Dinofia, MD, Alix E. Seif, MD, David T Teachey, MD, Diane Baniewicz, Colleen Callahan, Christina Fasano, Beth McBride, Vanessa Gonzalez, Farzana Nazimuddin, MS, David L. Porter, MD, Simon F Lacey, PhD BS, Carl H June, MD, Stephan A. Grupp, MD PhD, Shannon L. Maude, MD PhD

Blood (2018) 132 (Supplement 1): 556.

https://doi.org/10.1182/blood-2018-99-112572

Published: 2018

Journal Articles

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 1319.

https://doi.org/10.1182/blood.V130.Suppl_1.1319.1319

Published: 2017

Journal Articles

Severe Sepsis As Immune Stimulation and Protection from Relapse of Childhood Acute Lymphoblastic Leukemia (ALL): Results from a Pilot Study and Validation of Events in a National Administrative Dataset

Alix E. Seif, MD, Viviane C. Cahen, Yimei Li, PhD, Caitlin Walfoort Elgarten, MD, Amanda M. Dinofia, MD, Jennifer J. Wilkes, MD, Lena Winestone, MD, Yuan-Shung V. Huang, MS, Julie C Fitzgerald, MD, Brian T Fisher, DO, Gregor S. D. Reid, PhD, Kelly D Getz, Richard Aplenc, MD

Blood (2017) 130 (Supplement 1): 3445.

https://doi.org/10.1182/blood.V130.Suppl_1.3445.3445

Published: 2017

Journal Articles

Resource Utilization and Cost Analysis By Treatment Arm on the Children’s Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children’s Oncology Group

Amanda M. DiNofia, MD, Alix E. Seif, MD MPH, Meenakshi Devidas, PhD, Yimei Li, PhD, Matthew Hall, PhD, Yuan-Shung Vera Huang, MS, Rochelle Bagatell, MD, William L. Carroll, MD, Naomi J. Winick, MD, Stephen P. Hunger, MD, Brian T. Fisher, DO, MSCE, Eric C. Larsen, MD, Richard Aplenc, MD PhD

Blood (2014) 124 (21): 210.

https://doi.org/10.1182/blood.V124.21.210.210

Published: 2014

NARROW

Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents

IL-10 Levels Differentially Regulate IFNg Signaling of CART19 and CART22

Outcomes and Toxicities after Allogeneic Hematopoietic Cell Transplant for Remission Consolidation or Relapse Therapy after CD19 Chimeric Antigen Receptor T Cell Therapy in Children and Young Adults with Acute Lymphoblastic Leukemia

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL

Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019

Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy

Using Administrative Data to Identify Relapse and Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Lymphoblastic Leukemia (ALL): Validation at Two Centers and Incidence Estimation in a National Cohort

A Novel Approach to Identifying Septic Shock (SS) in Children with Acute Lymphoblastic Leukemia (ALL) Using Pediatric Health Information System (PHIS) Data: Methods Validation and Incidence Estimation in a National Cohort

Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Severe Sepsis As Immune Stimulation and Protection from Relapse of Childhood Acute Lymphoblastic Leukemia (ALL): Results from a Pilot Study and Validation of Events in a National Administrative Dataset

Resource Utilization and Cost Analysis By Treatment Arm on the Children’s Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children’s Oncology Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only